Summit Therapeutics Inc. (SMMT) is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to treat rare diseases and infectious diseases, particularly those for which no effective therapies currently exist. This dedication to finding and developing newer ways to address lesser explored but impactful health challenges makes Summit a unique entity in the pharmaceutical industry.
Concentrated mainly in two areas, Duchenne Muscular Dystrophy and Clostridioides difficile infection (CDI), Summit is empowering lives by bringing innovation and transforming treatment approaches for these severe conditions. Duchenne Muscular Dystrophy is a fatal genetic disease that causes muscle degeneration and premature death, usually in the early twenties. Summit is working on a potentially transformative therapy that could treat the underlying genetic cause and modify the disease course. In the case of C. difficile infections, Summit is developing a novel class of antibiotics that aims to safely eradicate the initial infection and protect against recurrent disease, a considerable challenge with this infection.
Headquartered in Cambridge, Massachusetts, Summit Therapeutics was incorporated in 2003. The company has strived to foster a culture of inclusivity and excellence, creating an environment for bright-minded scientists and professionals' capability to push the boundaries of medical understanding and patient care. The nature of Summit’s work is challenging, painstaking, and hugely significant, as it is driven by vast unmet medical needs that demand relentless scientific exploration and patient-centered commitment.
Working in close collaboration with world-leading institutions, Summit utilizes its unique platform technology and intelligence to deliver potentially life-changing therapies. The company works in a business model that emphasizes partnerships and collaborations that leverage its innovative technologies to develop superior pharmaceutical products.
Summit Therapeutics Inc. is publicly traded on the NASDAQ Stock Market under the ticker symbol "SMMT." Over the years, it has shown dedication through its innovative research and the development of novel, candidate drugs. Though the road to success in the pharmaceutical industry is long and requires considerable resources, Summit appears committed to its mission of bringing transformative medicines to patients suffering from rare and infectious diseases. The company's work speaks to the hope and promise of biotechnology - the concept of using our understanding of nature at the molecular level to solve some of humanity's most profound health challenges.